Table of Contents
ISRN Endocrinology
Volume 2013, Article ID 181240, 8 pages
http://dx.doi.org/10.1155/2013/181240
Review Article

Type 2 Diabetes Mellitus, Oral Diabetic Medications, Insulin Therapy, and Overall Breast Cancer Risk

Division of Endocrinology and Metabolism, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

Received 17 December 2012; Accepted 1 January 2013

Academic Editors: D. F. Skafar and J.-F. Tanti

Copyright © 2013 Hala Ahmadieh and Sami T. Azar. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Cancer Society, Cancer Facts & Figures 2012, American Cancer Society, Atlanta, Ga, USA, 2012.
  2. N. Howlader, A. M. Noone, M. Krapcho et al., Eds., SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute, Bethesda, MD, USA, 2012, based on November 2011 SEER data submission, posted to the SEER web site, http://seer.cancer.gov/csr/1975_2009_pops09/.
  3. S. Wild, G. Roglic, A. Green, R. Sicree, H. King, and Centers for Disease Control and Prevention, “National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States,” U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Ga, USA, 2011.
  4. Centers for Disease Control and Prevention, “Diabetes Report Card 2012, Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, Ga, USA,” 2012.
  5. K. Masur, F. Thévenod, and K. S. Znker, “Diabetes mellitus and breast cancer,” in Diabetes and Cancer. Epidemiological Evidence and Molecular Links. Front Diabetes, vol. 19, pp. 97–113, Karger, Basel, Switzerland, 2008. View at Google Scholar
  6. B. Arcidiacono, S. Iiritano, A. Nocera et al., “Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms,” Experimental Diabetes Research, vol. 2012, Article ID 789174, 12 pages, 2012. View at Publisher · View at Google Scholar
  7. F. de Waard and E. A. Baanders van Halewijn, “A prospective study in general practice on breast cancer risk in postmenopausal women,” International Journal of Cancer, vol. 14, no. 2, pp. 153–160, 1974. View at Google Scholar · View at Scopus
  8. B. A. O'Mara, T. Byers, and E. Schoenfeld, “Diabetes mellitus and cancer risk: a multisite case-control study,” Journal of Chronic Diseases, vol. 38, no. 5, pp. 435–441, 1985. View at Google Scholar · View at Scopus
  9. C. Unger, J. C. Rageth, P. Wyss, M. Spillmann, and E. Hochuli, “Risk factors in breast carcinoma,” Schweiz Med Wochenschr, vol. 121, pp. 30–36, 1991. View at Google Scholar
  10. E. Weiderpass, G. Gridlkey, I. Persson, O. Nyren, A. Ekbom, and H. O. Adami, “Risk of endometrial and breast cancer in patients with diabetes mellitus,” International Journal of Cancer, vol. 71, pp. 360–363, 1971. View at Google Scholar
  11. B. Attner, M. Landin-Olsson, T. Lithman, D. Noreen, and H. Olsson, “Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden,” Cancer Causes & Control, vol. 23, pp. 769–777, 2012. View at Google Scholar
  12. M. C. Hsieh, T. C. Lee, S. M. Cheng, S. T. Tu, M. H. Yen, and C. H. Tseng, “The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese,” Experimental Diabetes Research, vol. 2012, Article ID 413782, 6 pages, 2012. View at Publisher · View at Google Scholar
  13. S. Jordan, L. Lim, D. Vilainerun et al., “Breast cancer in the Thai Cohort Study: an exploratory case-control analysis,” Breast, vol. 18, no. 5, pp. 299–303, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Khachatryan, R. Scharpf, and S. Kagan, “Influence of diabetes mellitus type 2 and prolonged estrogen exposure on risk of breast cancer among women in Armenia,” Healthcare For Women International, vol. 32, pp. 953–971, 2011. View at Google Scholar
  15. H. O. Adami and A. Rimsten, “Prevalence of hypertension and diabetes in breast cancer: a case-control study in 179 patients and age-matched, non-hospitalized controls,” Clinical Oncology, vol. 4, no. 3, pp. 243–249, 1978. View at Google Scholar · View at Scopus
  16. M. Ragozzino, L. J. Melton, C. P. Chu, and P. J. Palumbo, “Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus,” Journal of Chronic Diseases, vol. 35, no. 1, pp. 13–19, 1982. View at Google Scholar · View at Scopus
  17. S. Kopp, S. Tanneberger, M. Mohner, and R. Kieser, “Diabetes and breast cancer risk,” International Journal of Cancer, vol. 46, no. 4, pp. 751–752, 1990. View at Google Scholar · View at Scopus
  18. S. Franceschi, C. la Vecchia, E. Negri, F. Parazzini, and P. Boyle, “Breast cancer risk and history of selected medical conditions linked with female hormones,” European Journal of Cancer, vol. 26, no. 7, pp. 781–785, 1990. View at Publisher · View at Google Scholar · View at Scopus
  19. H. O. Adami, J. McLaughlin, A. Ekbom et al., “Cancer risk in patients with diabetes mellitus,” Cancer Causes & Control, vol. 2, no. 5, pp. 307–314, 1991. View at Publisher · View at Google Scholar · View at Scopus
  20. C. La Vecchia, E. Negri, S. Franceschi, B. D’Avanzo, and P. Boyle, “A case-control study of diabetes mellitus and cancer risk,” British Journal of Cancer, vol. 70, pp. 950–953, 1994. View at Google Scholar
  21. H. Hjalgrim, M. Frisch, A. Ekbom, K. O. Kyvik, M. Melbye, and A. Green, “Cancer and diabetes: a follow-up study of two population- based cohorts of diabetic patients,” Journal of Internal Medicine, vol. 241, pp. 471–475, 1997. View at Google Scholar
  22. H. A. Weiss, L. A. Brinton, N. A. Potischman et al., “Breast cancer risk in young women and history of selected medical conditions,” International Journal of Epidemiology, vol. 28, no. 5, pp. 816–823, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. T. A. Sellers, J. M. Sprafka, S. M. Gapstur et al., “Does body fat distribution promote familial aggregation of adult onset diabetes mellitus and postmenopausal breast cancer?” Epidemiology, vol. 5, no. 1, pp. 102–108, 1994. View at Google Scholar · View at Scopus
  24. G. Chodick, A. D. Heymann, L. Rosenmann et al., “Diabetes and risk of incident cancer: a large population-based cohort study in Israel,” Cancer Causes & Control, vol. 21, no. 6, pp. 879–887, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. S. L. Bowker, K. Richardson, C. A. Marra, and J. A. Johnson, “Risk of breast cancer after onset of type 2 diabetes: evidence of detection bias in postmenopausal women,” Diabetes Care, vol. 34, pp. 2542–2544, 2011. View at Google Scholar
  26. K. B. Michels, C. G. Solomon, F. B. Hu et al., “Type 2 diabetes and subsequent incidence of breast cancer in the nurses' health study,” Diabetes Care, vol. 26, no. 6, pp. 1752–1758, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. S. C. Larsson, C. S. Mantzoros, and A. Wolk, “Diabetes mellitus and risk of breast cancer: a meta-analysis,” International Journal of Cancer, vol. 121, no. 4, pp. 856–862, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Cleveland, K. North, J. Stevens, S. Teitelbaum, A. Neugut, and M. Gammon, “The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project,” Cancer Causes & Control, vol. 23, pp. 1193–1203, 2012. View at Publisher · View at Google Scholar
  29. R. T. Chlebowski, A. McTiernan, J. Wactawski-Wende et al., “Diabetes, metformin, and breast cancer in postmenopausal women,” Journal of Clinical Oncology, vol. 30, pp. 2844–2852, 2012. View at Google Scholar
  30. M. T. Redaniel, M. Jeffreys, M. T. May, Y. Ben-Shlomo, and R. M. Martin, “Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women,” Cancer Causes & Control, vol. 23, no. 11, pp. 1785–1795, 2012. View at Publisher · View at Google Scholar
  31. W. W. Chen, Y. Y. Shao, W. Y. Shau et al., “The impact of diabetes mellitus on prognosis of early breast cancer in Asia,” Oncologist, vol. 17, no. 4, pp. 485–491, 2012. View at Publisher · View at Google Scholar
  32. M. A. Kaplan, Z. Pekkolay, M. Kucukoner et al., “Type 2 diabetes mellitus and prognosis in early stage breast cancer women,” Medical Oncology, vol. 29, no. 3, pp. 1576–1580, 2012. View at Google Scholar
  33. C. Villarreal-Garza, R. Shaw-Dulin, F. Lara-Medina et al., “Impact of diabetes and hyperglycemia on survival in advanced breast cancer patients,” Experimental Diabetes Research, vol. 2012, Article ID 732027, 8 pages, 2012. View at Publisher · View at Google Scholar
  34. D. J. Magliano, W. A. Davis, J. E. Shaw, D. G. Bruce, and T. M. E. Davis, “Incidence and predictors of all-cause and site-specific cancer in type 2 diabetes: the Fremantle Diabetes Study,” European Journal of Endocrinology, vol. 167, pp. 589–599, 2012. View at Google Scholar
  35. P. Boyle, M. Boniol, A. Koechlin et al., “Diabetes and breast cancer risk: a meta-analysis,” British Journal of Cancer, vol. 107, no. 9, pp. 1608–1617, 2012. View at Publisher · View at Google Scholar
  36. A. L. Ronco, E. De Stefani, H. Deneo-Pellegrini, and A. Quarneti, “Diabetes, overweight and risk of postmenopausal breast cancer: a case-control study in Uruguay,” The Asian Pacific Journal of Cancer Prevention, vol. 13, no. 1, pp. 139–146, 2012. View at Google Scholar
  37. B. R. Muck, S. Trotnow, and G. Hommel, “Cancer of the breast, diabetes and pathological glucose tolerance,” Archiv fur Gynakologie, vol. 220, no. 1, pp. 73–81, 1975. View at Google Scholar · View at Scopus
  38. H. O. Adami and A. Rimsten, “Prevalence of hypertension and diabetes in breast cancer: a case-control study in 179 patients and age-matched, non-hospitalized controls,” Clinical Oncology, vol. 4, no. 3, pp. 243–249, 1978. View at Google Scholar · View at Scopus
  39. E. Weiderpass, G. Gridley, I. Persson, O. Nyren, A. Ekbom, and H. O. Adami, “Risk of endometrial and breast cancer in patients with diabetes mellitus,” International Journal of Cancer, vol. 71, pp. 360–363, 1997. View at Google Scholar
  40. P. J. Mink, E. Shahar, W. D. Rosamond, A. J. Alberg, and A. R. Folsom, “Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study,” American Journal of Epidemiology, vol. 156, no. 4, pp. 349–352, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. L. L. Lipscombe, P. J. Goodwin, B. Zinman, J. R. McLaughlin, and J. E. Hux, “Increased prevalence of prior breast cancer in women with newly diagnosed diabetes,” Breast Cancer Research and Treatment, vol. 98, no. 3, pp. 303–309, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. F. De Waard and E. A. Baanders van Halewijn, “A prospective study in general practice on breast cancer risk in postmenopausal women,” International Journal of Cancer, vol. 14, no. 2, pp. 153–160, 1974. View at Google Scholar · View at Scopus
  43. D. A. Lawlor, G. D. Smith, and S. Ebrahim, “Hyperinsulinaemia and increased risk of breast cancer: findings from the British women's heart and health study,” Cancer Causes & Control, vol. 15, no. 3, pp. 267–275, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. L. L. Lipscombe, P. J. Goodwin, B. Zinman, J. R. McLaughlin, and J. E. Hux, “Diabetes mellitus and breast cancer: a retrospective population-based cohort study,” Breast Cancer Research and Treatment, vol. 98, no. 3, pp. 349–356, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. P. K. Chaudhuri, B. Chaudhuri, and N. Patel, “Modulation of estrogen receptor by insulin and its biologic significance,” Archives of Surgery, vol. 121, no. 11, pp. 1322–1325, 1986. View at Google Scholar · View at Scopus
  46. E. Guastamacchia, F. Resta, A. Mangia et al., “Breast cancer: biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets,” Current Drug Targets. Immune, Endocrine and Metabolic Disorders, vol. 3, no. 3, pp. 205–209, 2003. View at Google Scholar · View at Scopus
  47. J. M. M. Evans, L. A. Donnelly, A. M. Emslie-Smith, D. R. Alessi, and A. D. Morris, “Metformin and reduced risk of cancer in diabetic patients,” British Medical Journal, vol. 330, no. 7503, pp. 1304–1305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. S. L. Bowker, S. R. Majumdar, P. Veugelers, and J. A. Johnson, “Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin,” Diabetes Care, vol. 29, no. 2, pp. 254–258, 2006. View at Google Scholar · View at Scopus
  49. M. Monami, C. Lamanna, D. Balzi, N. Marchionni, and E. Mannucci, “Sulphonylureas and cancer: a case-control study,” Acta Diabetologica, vol. 46, no. 4, pp. 279–284, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. G. Libby, L. A. Donnelly, P. T. Donnan, D. R. Alessi, A. D. Morris, and J. M. M. Evans, “New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes,” Diabetes Care, vol. 32, no. 9, pp. 1620–1625, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. N. F. Col, L. Ochs, V. Springmann, A. K. Aragaki, and R. T. Chlebowski, “Metformin and breast cancer risk: a meta-analysis and critical literature review,” Breast Cancer Research and Treatment, vol. 135, no. 3, pp. 639–646, 2012. View at Google Scholar
  52. M. Bodmer, C. Meier, S. Krähenbühl, S. S. Jick, and C. R. Meier, “Long-term metformin use is associated with decreased risk of breast cancer,” Diabetes Care, vol. 33, no. 6, pp. 1304–1308, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. J. L. F. Bosco, S. Antonsen, H. T. Sorensen, L. Pedersen, and T. L. Lash, “Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark,” Cancer Epidemiology Biomarkers and Prevention, vol. 20, no. 1, pp. 101–111, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. M. C. Towler and D. G. Hardie, “AMP-activated protein kinase in metabolic control and insulin signaling,” Circulation Research, vol. 100, no. 3, pp. 328–341, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. R. J. Shaw, K. A. Lamia, D. Vasquez et al., “Medicine: the kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin,” Science, vol. 310, no. 5754, pp. 1642–1646, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Jalving, J. A. Gietema, J. D. Lefrandt et al., “Metformin: taking away the candy for cancer?” European Journal of Cancer, vol. 46, no. 13, pp. 2369–2380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. D. A. Guertin and D. M. Sabatini, “Defining the role of mTOR in cancer,” Cancer Cell, vol. 12, no. 1, pp. 9–22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. K. N. Phoenix, F. Vumbaca, and K. P. Claffey, “Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model,” Breast Cancer Research and Treatment, vol. 113, no. 1, pp. 101–111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. K. A. Brown, N. I. Hunger, M. Docanto, and E. R. Simpson, “Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase,” Breast Cancer Research and Treatment, vol. 123, no. 2, pp. 591–596, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. Y. Fierz, R. Novosyadlyy, A. Vijayakumar, S. Yakar, and D. LeRoith, “Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression,” Diabetes, vol. 59, no. 3, pp. 686–693, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Schott, A. Bierhaus, F. Schuetz et al., “Therapeutic effects of metformin in breast cancer: involvement of the immune system?” Cancer Immunology, Immunotherapy, vol. 60, pp. 1221–1225, 2011. View at Google Scholar
  62. S. Jiralerspong, S. L. Palla, S. H. Giordano et al., “Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer,” Journal of Clinical Oncology, vol. 27, no. 20, pp. 3297–3302, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. K. Hosono, H. Endo, H. Takahashi et al., “Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial,” Cancer Prevention Research, vol. 3, pp. 1077–1083, 2010. View at Google Scholar
  64. S. Niraula, V. Stambolic, R. J. O. Dowling et al., “Clinical and biologic effects of metformin in early stage breast cancer,” Cancer Research, vol. 70, no. 24, supplement, p. 104s, 2010, abstract no. PD03-06. View at Google Scholar
  65. S. M. Hadad, J. A. Dewar, E. Elseedawy et al., “Gene signature of metformin actions on primary breast cancer within a window of opportunity randomized clinical trial,” Journal of Clinical Oncology, vol. 28, supplement, 2010, abstract no. 560. View at Google Scholar
  66. “A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer,” vol. 8, 2011.
  67. M. Cazzaniga, B. Bonanni, A. Guerrieri-Gonzaga, and A. Decensi, “Is it time to test metformin in breast cancer clinical trials?” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 3, pp. 701–705, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. P. Muti, F. Berrino, V. Krogh et al., “Metformin, diet and breast cancer: an avenue for chemoprevention,” Cell Cycle, vol. 8, no. 16, p. 2661, 2009. View at Google Scholar · View at Scopus
  69. B. Martin-Castillo, J. Dorca, A. Vazquez-Martin et al., “Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology,” Annals of Oncology, vol. 21, no. 1, pp. 187–189, 2010. View at Google Scholar · View at Scopus
  70. C. Koro, S. Barrett, and N. Qizilbash, “Cancer risks in thiazolidinedione users compared to other anti-diabetic agents,” Pharmacoepidemiology and Drug Safety, vol. 16, no. 5, pp. 485–492, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. H. J. Burstein, G. D. Demetri, E. Mueller, P. Sarraf, B. M. Spiegelman, and E. P. Winer, “Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a phase II study,” Breast Cancer Research and Treatment, vol. 79, no. 3, pp. 391–397, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. X. He, F. J. Esteva, J. Ensor, G. N. Hortobagyi, M. H. Lee, and S. C. Yeung, “Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer,” Annals of Oncology, vol. 23, no. 7, pp. 1771–1780, 2012. View at Publisher · View at Google Scholar
  73. P. S. Wang, F. S. Chou, M. Bloomston et al., “Thiazolidinediones downregulate Wnt/β-Catenin signaling via multiple mechanisms in breast cancer cells,” Journal of Surgical Research, vol. 153, no. 2, pp. 210–216, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. C. H. Chang, J. W. Lin, L. C. Wu, M. S. Lai, and L. M. Chuang, “Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 7, pp. 1170–1175, 2012. View at Google Scholar
  75. T. Salvatore, O. Carbonara, D. Cozzolino, R. Torella, and F. C. Sasso, “Progress in the oral treatment of type 2 diabetes: update on DPP-IV inhibitors,” Current Diabetes Reviews, vol. 5, no. 2, pp. 92–101, 2009. View at Google Scholar
  76. M. Janghorbani, M. Dehghani, and M. Salehi-Marzijarani, “Systematic review and meta-analysis of insulin therapy and risk of cancer,” Hormones and Cancer, vol. 3, no. 4, pp. 137–146, 2012. View at Google Scholar
  77. J. A. Koehler and D. J. Drucker, “Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells,” Diabetes, vol. 55, no. 5, pp. 1369–1379, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Janghorbani, M. Dehghani, and M. Salehi-Marzijarani, “Systematic review and meta-analysis of insulin therapy and risk of cancer,” Hormones and Cancer, vol. 3, no. 4, pp. 137–146, 2012. View at Publisher · View at Google Scholar
  79. S. Suissa, L. Azoulay, S. Dell'Aniello, M. Evans, J. Vora, and M. Pollak, “Long-term effects of insulin glargine on the risk of breast cancer,” Diabetologia, vol. 54, no. 9, pp. 2254–2262, 2011. View at Google Scholar
  80. The ORIGIN Trial Investigators, “Basal insulin and cardiovascular and other outcomes in dysglycemia,” The New England Journal of Medicine, vol. 367, pp. 319–328, 2012. View at Google Scholar